Antidiabetic Drugs in Combination with Hydroxychloroquine Improve Glycemic Control in Alloxan Induced Diabetic Rats

Shaheda Zannah, Md. Saiful Islam, A. F. M. Towheedur Rahman, Md. Asaduzzaman, Abdul Alim Al Bari, Yusuf Ali, Gazi Jahirul Islam, A. H. M. Khurshid Alam, Hazrat Ali, Mamunur Rashid

Department of Chemistry, Khulna University of Engineering and Technology, Khulna, Bangladesh.
Department of Pharmacy, University of Rajshahi, Rajshahi, Bangladesh.

DOI: 10.4236/pp.2014.57082                

Abstract

Worldwide prevalence of diabetes mellitus has become an issue of great concern in current decades. This life threatening disease is associated with worsening of glycemic control and progressive metabolic dysfunctions. Objective: Current study aimed to investigate the effect of hydroxychloroquine (HCQ) as an adjunct to glibenclamide or metformin on glycemic control in alloxan induced diabetic rats. Methods: HCQ was combined separately with two conventional anti-diabetic drugs; glibenclamide and metformin. At first, alloxan (120 mg/kg) induced diabetic rats were treated with single dose of metformin (850 mg/70 kg BW), glibenclamide (10 mg/70 kg BW) and HCQ (300 mg/70 kg BW) intraperitoneally once daily for two weeks. Then non fixed dose combinations of glibenclamide (5 mg/70 kg BW) with HCQ (150 mg/70 kg BW) and metformin (425 mg/70 kg BW) with HCQ (150 mg/70 kg BW) were injected along with those of the three drugs alone once daily for four weeks. Results: In alloxan induced diabetic rats, glibenclamide, metformin and their combination therapies reduced blood glucose level significantly but combination therapies are the most effective. Glibenclamide or metformin in combination with HCQ also significantly (P < 0.05) reduced the elevated levels of total cholesterol, triglycerides, and low density lipoprotein cholesterol (LDL-C) level and increased high density lipoprotein cholesterol (HDL-C) level. Moreover, HCQ potentiates the liver glycogen synthesis of metformin or glibenclamide. Conclusion: Outcomes of this investigation indicate that combination of glibenclamide or metformin with HCQ improves glycemic control and provides additional metabolic benefits, not achieved with either glibenclamide or metformin alone.

Keywords

Diabetes Mellitus, Glycemic Control, HCQ, Glibenclamide, Metformin

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	The Diabetes Control and Complications Trial (DCCT) Research Group (1993) The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in the Diabetes Control in Insulin Dependent Diabetes Mellitus. The New England Journal of Medicine, 329, 977-986. http://dx.doi.org/10.1056/NEJM199309303291401
[2]	UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes. The Lancet, 352, 837-853. http://dx.doi.org/10.1016/S0140-6736(98)07019-6
[3]	Turner, R.C., Cull, C.A., Frighi, V., et al. (1999) Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies. UK Prospective Diabetes Study (UKPDS) Group. The Journal of the American Medical Association, 281, 2005-2012. http://dx.doi.org/10.1001/jama.281.21.2005
[4]	UK Prospective Diabetes Study Group (1995) UK Prospective Diabetes Study 16: Overview of 6 Years’ Therapy of Type II Diabetes: A Progressive Disease. Diabetes, 44, 1249-1258. http://dx.doi.org/10.2337/diab.44.11.1249
[5]	Yale, J.F., Valiquett, T.R., Ghazzi, M.N., et al. (2001) The Effect of a Thiazolidinedione Drug, Troglitazone, on Glycemia in Patients with Type 2 Diabetes Mellitus Poorly Controlled with Sulfonylurea and Metformin. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Annals of Internal Medicine, 134, 737-745. http://dx.doi.org/10.7326/0003-4819-134-9_Part_1-200105010-00010
[6]	Cook, M.N., Girman, C.J., Stein, P.P., et al. (2005) Glycemic Control Continues to Deteriorate after Sulfonylureas Are Added to Metformin among Patients with Type 2 Diabetes. Diabetes Care, 28, 995-1000. http://dx.doi.org/10.2337/diacare.28.5.995
[7]	Robertson, R.P. (2004) Chronic Oxidative Stress as a Central Mechanism for Glucose Toxicity in Pancreatic Islet Beta Cells in Diabetes. The Journal of Biological Chemistry, 279, 42351-42354. http://dx.doi.org/10.1074/jbc.R400019200
[8]	Robertson, R.P. and Harmon, J.S. (2006) Diabetes, Glucose Toxicity, and Oxidative Stress: A Case of Double Jeopardy for the Pancreatic Islet Beta Cell. Free Radical Biology and Medicine, 41, 177-184. http://dx.doi.org/10.1016/j.freeradbiomed.2005.04.030
[9]	Grankvist, K., Marklund, S.L. and Taljedal, I.B. (1981) CuZn-Superoxide Dismutase, Mn-Superoxide Dismutase, Catalase and Glutathione Peroxidase in Pancreatic Islets and Other Tissues in the Mouse. Biochemical Journal, 199, 393-398.
[10]	Kajimoto, Y. and Kaneto, H. (2004) Role of Oxidative Stress in Pancreatic Beta-Cell Dysfunction. Annals of the New York Academy of Sciences, 1011, 168-176. http://dx.doi.org/10.1196/annals.1293.017
[11]	Emami, J., Pasutto, F.M., Mercer, J.R., et al. (1999) Inhibition of Insulin Metabolism by Hydroxychloroquine and Its Enantiomers in Cytosolic Fraction of Liver Homogenates from Healthy and Diabetic Rats. Life Sciences, 64, 325-335. http://dx.doi.org/10.1016/S0024-3205(98)00568-2
[12]	Petri, M. (1996) Hydroxychloroquine Use in the Baltimore Lupus Cohort: Effects on Lipids, Glucose and Thrombosis. Lupus, 5, 16-22. http://dx.doi.org/10.1177/096120339600500105
[13]	Wasko, M.C.M., Hubert, H.B. and Lingala, V.B. (2007) Hydroxychloroquine and Risk of Diabetes in Patients with Rheumatoid Arthritis. The Journal of the American Medical Association, 298, 187-193. http://dx.doi.org/10.1001/jama.298.2.187
[14]	Iams, S.G. and Wexler, B.C. (1977) Alloxan Diabetes in Spontaneously Hypertensive Rats: Gravimetric, Metabolic and Histopathological Alterations. British Journal of Experimental Pathology, 58, 177-199.
[15]	Halliwell, B. and Gutteridge, J.M.C. (1989) Free Radicals in Biology and Medicine. 2nd Edition, Clarendon Press, Oxford.
[16]	Krentz, A.J. and Bailey, C.J. (2005) Oral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus. Drugs, 65, 385-411. http://dx.doi.org/10.2165/00003495-200565030-00005
[17]	Wiernsperger, N.F. and Bailey, C.J. (1999) The Antihyperglycaemic Effect of Metformin: Therapeutic and Cellular Mechanisms. Drugs, 58, 31-39. http://dx.doi.org/10.2165/00003495-199958001-00009
[18]	Cynober, L., Aussel, C., Vaubourdolle, M., et al. (1987) Modulation of Insulin Action on 2-Deoxyglucose Uptake by Chloroquine in Chick Embryo Fibroblast. Diabetes, 36, 27-32. http://dx.doi.org/10.2337/diab.36.1.27
[19]	Asamoah, K.A., Robb, D.A. and Furman, B.L. (1990) Chronic Chloroquine Treatment Enhances Insulin Release in Rats. Diabetes Research and Clinical Practice, 9, 273-278. http://dx.doi.org/10.1016/0168-8227(90)90056-Y
[20]	Emami, J., Pasutto, F.M., Mercer, J.R., et al. (1998) Inhibition of Insulin Metabolism by Hydroxychloroquine and Its Enantiomers in Cytosolic Fraction of Liver Homogenates from Healthy and Diabetic Rats. Life Sciences, 64, 325-335. http://dx.doi.org/10.1016/S0024-3205(98)00568-2
[21]	Emami, J., Gerstein, H.C., Pasutto, F.M. et al. (1999) Insulin Sparing Effect of Hydroxychloroquinein Diabetic Rats Is Concentration Dependent. Canadian Journal of Physiology and Pharmacology, 77, 118-123. http://dx.doi.org/10.1139/y98-146
[22]	Ohno, T., Horio, F., Tanaka, S., et al. (2000) Fatty Liver and Hyperlipidemia in IDDM (Insulin-Dependent Diabetes Mellitus) of Streptozotocin-Treated Shrews. Life Sciences, 66, 125-131. http://dx.doi.org/10.1016/S0024-3205(99)00570-6
[23]	Coppack, S.W., Jensen, M.D. and Miles, J.M. (1994) In Vivo Regulation of Lipolysis in Humans. Journal of Lipid Resesrch, 35, 177-193.
[24]	Winocour, P.H., Durrington, P.N., Bhatnagar, D., et al. (1992) Abnormalities of VLDL, IDL, and LDL Characterize Insulin-Dependent Diabetes Mellitus. Arteriosclerosis, Thrombosis and Vascular Biology, 12, 920-928. http://dx.doi.org/10.1161/01.ATV.12.8.920
[25]	Verges, B.L. (1999) Dyslipidemia in Diabetes Mellitus. Review of the Main Lipoprotein Abnormalities and Their Consequences on the Development of Atherogenesis. Diabetes and Metabolism, 25, 32-40.
[26]	Defronzo, R.A. and Goodman, A.M. (1995) Efficacy of Metformin in Patient with Non-Insulin-Dependent Diabetes Mellitus. The New England Journal of Medicine, 333, 541-549. http://dx.doi.org/10.1056/NEJM199508313330902
[27]	Chehade, J.M. and Mooradian, A.D. (2000) A Rational Approach to Drug Therapy of Type-2 Diabetes Mellitus. Drugs, 60, 95-113. http://dx.doi.org/10.2165/00003495-200060010-00006
[28]	Grover, J.K., Vats, V. and Rathi, S.S. (2000) Antihyperglycemic Effect of Eugenia jambolana and Tinosporacardifolia in Experimental Diabetes and Their Effects on Key Metabolic Enzymes Involved in Carbohydrate Metabolism. Journal of Ethnopharmacology, 73, 461-470. http://dx.doi.org/10.1016/S0378-8741(00)00319-6
[29]	Gold, A.H. (1970) The Effect of Diabetes and Insulin on Liver Glycogen Synthetase Activation. The Journal of Biological Chemistry, 245, 903-905.
[30]	Goel, R.K., Mahajan, M.P. and Kulkarni, S.K. (2004) Evaluation of Antihyperglycemic Activity of Some Novel Monocyclic Beta Lactams. Journal of Pharmacy and Pharmaceutical Sciences, 7, 80-83.